In the univariate logistic regression analysis for adverse events of grade ≥3 neurologic events, grade ≥3 infections, or grade ≥3 cytokine release syndrome, none of the examined biomarkers were significant for either treatment group, including percentage of bone marrow blasts, blast count, absolute count of CD45+ CD3+ CD8+ cells, percentage of CD45+ CD3+ CD8+ cells, absolute count of CD3+ cells, percentage of CD3+ cells, absolute count of CD3− CD19+cells and percentage of CD3− CD19+ cells (Table 2). This evidence concerns the gene CD19 and infection.